From Documents to Defensible Decisions
Black‑box models lack trust & traceability. We provide verifiable Claim Graphs that enable customizable, auditable AI in a ~$36B enterprise knowledge‑graph market.
Pre-Seed Round
November 2025 | amini@deepentix.com
The Problem
Verifiable decisions are slow and inconsistent.
Pharmaceuticals / MedTech
- MANUAL: Our pharma pilot partner reviews 15 Clinical Trial Reports (CTRs) / day out of 15,000 to cover!
- FRAGMENTED: Information is scattered across siloed systems.
- UNAUDITABLE: Current processes lack clear provenance and audit trails for verifiable decisions.
Insurance
- STP STALLS: Underwriters manually review policy requests, creating bottlenecks and delaying quotes.
- INCONSISTENT: Individual decisions lead to inconsistent risk assessment.
- NO MEMORY: Lack of insight from previously processed cases hinders efficiency and accuracy.
What's missing?
A trustworthy, claim‑centric source of truth with full provenance from Answer → Claim → Paragraph → Document → Author.
The Solution
Specialized Claim Graphs
We turn documents into verifiable Claim Graphs that LLMs can trust at enterprise scale.
Core IP:
- Hierarchical Semantic Claims (HSC): multi-level claims knowledge graph, highly interpretable, grounding consuming LLM-s with connected facts and multi-hop reasoning.
- Scalable Extraction via Tuned SLMs: configurable tuned SLMs, 10x cheaper than 50-70B level models, and higher quality (claims paraphrasing, triple extraction, supporting references), reduction in hallucination.
- Going (much) smaller with SLM-s: Hypothesis: small highly specialized models beat large generic ones
a) cost (by factors)
b) quality for granular enough tasks.
- Provenance Chain: Answer → Claim → Paragraph → Document → Author
- Reasoning Plane (beyond RAG): graph‑constrained reasoning and counterfactual checks (policy clauses, CER inclusion criteria) for audit‑grade decisions.
The Solution
From Answer to Author — Gap Finder Demo
Founders
Morteza Amini
CEO
CEO
- 3x tech startup founder
- Users from 150+ countries with 5-star reviews
- PhD Numerical BioMech, TU Wien (250+ citations)
Endri Deliu
CTO
CTO
- Ex-Salesforce ML Architect
- 15 years Silicon Valley enterprise AI experience
- AI Fellow, EuroCC Austria
Ali Khalili
CKO
CKO
- Sr. Mgr. Deloitte, Leading Knowledge-enriched AI
- Sr. Res. Fellow Knowledge Rep., VU Amsterdam
- PhD Knowledge Eng. (50+ publications), U Leipzig
Altan Nar
CFO
CFO
- CFA charterholder
- $10M+ raised across 3 companies
- 34% MoM growth track record
Traction
Customers
- Pilot 1 (Pharma, Switzerland): Auditable protocol workflow automation.
- Pilot 2 (Pharma, Germany): New drug competitor analysis pipeline.
- MVP (Biomed., SciPub+): Knowledge gap-based hypothesis generator.
- 5 new pilots planned for 2026
Grants and Partners
- €270k aws DeepTech Grant.
- €2.5M grant pipeline
- TIB partnership: collaboration on the expert SLM project with Prof. Auer's team at the TIB with iver 2 decades of experience in Neurosymbolic Graphs
Why Now
Regulatory Catalyst
EU AI Act + Solvency II make explainability mandatory. Claim‑level provenance turns compliance from manual to built‑in.
Economic Incentive
CER rework and claims appeals are costly. Verifiable answers shorten reviews, reduce rework, and unlock STP.
Technological Shift
95% of AI enterprise pilots have not led to any ROI (MIT, 2025). Graph x GenAI is mainstream. Big gap in specialized solutions remain open.
Market Size:
€37B
Total Addressable Market
AI Middleware & Knowledge Graphs (2025)
€1.8B
Serviceable Addressable Market
EU Pharma/MedTech & BFSI (2025)
€15M
Beachhead Market
DACH Pharma/MedTech + Insurers
Competitive Insight
Legend: ✅ native • ◑ partial/via partner/custom • ✕ not core
Business Model
GaaS + Usage-Based Pricing
Usage‑based (Hosted GaaS)
€0.02 per API call/query
We host and operate the graph;
Free graph indexing with a 12‑month contract. Simple pricing; we will adjust as we learn.
On‑prem / Self‑hosted
€80k/year license
Customer runs their own graph;
Customer bears infrastructure/cloud costs
Free Trial (3 months):
Up to 1,000 documents / 20k claims ingested and 1,000 API calls included.
Enterprise add‑ons
Private SLMs, custom ontologies, fine‑tuned deep research tools, audit exports.
Go-to-Market Strategy
Who we target:
- Related solution vendors
- Consultancies/boutiques (e.g., Deloitte partner units)
Social Proof:
- CTO's 15+ yrs experience with SV Enterprise AI solutions
- CKO’s 10+ yrs as Senior Knowledge Solutions Manager @ Deloitte → partner pathways.
- Pilot success
Identify Key Enterprise Players
LinkedIn / Email Outreach
Discovery Call
Loop in Current Vendor
Data mgmt / automation / software
Provide Pain-Specific Content
Live Solution Demo
Pilot Program
RoadMap & Funding
2024
Project start
INiTS incubation
€100K De-minimis
€100K Founders' in-kind
€100K Founders' in-kind
2025
Team of 5
MVP + PoC in Pharma
€270K Grant
€230K Founders' cash & in-kind
€230K Founders' cash & in-kind
2026
Team of 9
3+2 Pilots in Pharma & InsurTech
Technology Validated ✅
Technology Validated ✅
€200K Grant
€150K Angel co-invest
€1.2M Pre-seed
€150K Angel co-invest
€1.2M Pre-seed
2027
Team of 15
Product-Market Fit (5M ARR)
€1.5M Grant
€3M Seed
€3M Seed
Next Steps
Contact: Morteza Amini, CEO amini@deepentix.com
NOTE: This deck contains confidential information. Please do not distribute.